aqp

DFP00173 is a potent and selective aquaporin 3 (AQP3) inhibitor, with an IC50 of approximately 0.1-0.4 μM for both mouse and human AQP3. It demonstrates selectivity for AQP3 compared to homologous AQP subtypes AQP7 and AQP9.

TC-AQP1-1 is a blocker of the aquaporin 1 channel identified by virtual screening and inhibits water flux through hAQP1 in Xenopus laevis oocyte swelling assays at low micromolar concentrations.

AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. This compound can induce experimental autoimmune encephalomyelitis (EAE), characterized by midline brain lesions, retinal abnormalities, and lesions at the grey/white matter boundary of the spinal cord. AQP-4 is the target antigen in neuromyelitis optica.

AQP4 (201-220) is the encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE), characterized by midline brain lesions, retinal lesions, and lesions at the gray matter/white matter boundary of the spinal cord. AQP-4 is the target antigen in neuromyelitis optica.

AQP3-IN-1 (compounds 3), an AQP3 inhibitor, exhibits an IC 50 of 8.91 μM and effectively inhibits melanoma cell proliferation [1].

AQP4 (205-215) is a fragment of the water channel protein Aquaporin-4 (AQP4). This protein is an autoimmune antigen in optic neuromyelitis and, upon binding with CD40, is upregulated and presented in B cells. AQP4 is associated with neuromyelitis optica (NMO), an autoimmune inflammatory disease of the central nervous system (CNS).

AQP4 (205-215) TFA is a fragment of the water channel protein-4 (AQP4). AQP4 acts as an autoimmune antigen in neuromyelitis optica, upregulating and presenting in B cells upon binding with CD40. AQP4 is associated with neuromyelitis optica (NMO), an autoimmune inflammatory disease of the central nervous system (CNS).